What's Happening?
The U.S. Department of Labor has issued a final rule requiring pharmacy benefit managers (PBMs) to disclose to large employer health plans the amounts they collect from drug manufacturer rebates, spread pricing, and pharmacy clawbacks. This rule applies
to self-insured plans with 100 or more participants or those offered by employers with at least 100 employees. The requirements will take effect for plan years beginning on or after July 1, 2027. The rule does not aim to set drug prices or cap PBM fees but rather to provide employers with the necessary information and audit rights to assess the reasonableness of PBM charges. Daniel Aronowitz, assistant secretary of the Labor Department's Employee Benefits Security Administration, highlighted that healthcare is often the second-largest operating expense for employers, yet they frequently lack transparency into PBM compensation. Rep. Bobby Scott of Virginia, the top Democrat on the House Education and Workforce Committee, has urged the department to expand the rule to include insurers acting as PBMs for fully insured plans and fees charged by third-party administrators.
Why It's Important?
This rule is significant because it aims to increase transparency in the complex prescription drug supply chain, potentially leading to lower healthcare costs for large employers and, indirectly, for their employees. Employers, who bear the majority of prescription costs, often pass these expenses onto workers through premiums, deductibles, and wages. By gaining insight into PBM compensation structures, employers will be better equipped to negotiate more favorable terms, which could translate into savings. The lack of transparency has historically made it difficult for plans to ascertain the true cost of PBM services. Pharmacists have welcomed the rule, with Ronna Hauser of NCPA noting that employers have been 'kept in the dark for many years.' The Labor Department projects that this rule could reduce prescription drug costs by up to $22 billion over a decade, although actual savings will depend on how employers utilize the newly available information.
What's Next?
The rule will take effect 60 days after its publication in the Federal Register, with the first disclosures expected for plan years commencing July 1, 2027. Employers will need to review their current PBM contracts to ensure they allow for full audits and access to rebate data in preparation for 2027 renewals. Brokers and consultants affiliated with PBMs will also be required to disclose their compensation, enabling employers to better judge the independence of the advice they receive. For individual patients, immediate changes at the pharmacy counter are not expected, as copays, formularies, and prior authorization rules will remain until plans renegotiate contracts. Workers with chronic conditions who rely on expensive brand-name prescriptions stand to benefit most if increased transparency leads to lower drug costs, as rebates on these drugs are often substantial but rarely reach patients directly.
Beyond the Headlines
This regulatory change highlights a broader push for transparency in the healthcare industry, particularly concerning the opaque practices of PBMs. The rule addresses the ethical implications of PBMs profiting from undisclosed spread pricing and manufacturer rebates, which can inflate drug costs for plans and patients. Legally, it empowers plan fiduciaries with audit rights, allowing them to scrutinize PBM financial dealings more thoroughly. The rule also underscores the ongoing debate about the scope of federal oversight in healthcare, as evidenced by Rep. Bobby Scott's call for broader application to fully insured plans. This development could trigger long-term shifts in how PBMs operate, potentially fostering a more competitive and accountable market for prescription drug benefits, ultimately influencing public policy discussions around drug pricing and healthcare affordability.
